Amgen Inc. $AMGN Stock: Keybank National Association OH Cuts Holdings

Keybank National Association OH lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 230,772 shares of the medical research company’s stock after selling 10,471 shares during the quarter. Keybank National Association OH’s holdings in Amgen were worth $97,273,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quest 10 Wealth Builders Inc. grew its position in Amgen by 220.0% in the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after acquiring an additional 55 shares during the period. Wellington Altus USA Inc. increased its stake in Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after acquiring an additional 34 shares during the last quarter. Nvwm LLC raised its position in Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the period. PFS Partners LLC raised its position in Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 42 shares during the period. Finally, TOWER TRUST & INVESTMENT Co purchased a new stake in Amgen in the third quarter valued at $38,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. BMO Capital Markets decreased their price target on Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research note on Monday, October 12th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Robert W. Baird boosted their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. Sanford C. Bernstein boosted their price objective on shares of Amgen from $345.00 to $400.00 and gave the company a “market perform” rating in a report on Wednesday, November 4th. Finally, HSBC cut shares of Amgen from a “buy” rating to a “hold” rating and decreased their target price for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $422.76.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

NASDAQ:AMGN opened at $465.23 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. The stock’s fifty day moving average is $423.79 and its two-hundred day moving average is $379.39. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The stock has a market capitalization of $251.65 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same period last year, the business posted $5.64 earnings per share. The company’s quarterly revenue was up 8.5% on a year-over-year basis. Research analysts anticipate that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio is presently 58.47%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.